Mountain Crest V to combine with AUM Biosciences at ~$400M valuation; PIPE of $30M sought

Mountain Crest Acquisition Corp. V

Purchase price of ~$400M; AUM shareholders roll over 100% equity for ~84% of pro forma ownership.
Targeted PIPE of $30M (not committed) to fund AUM balance sheet and transaction expenses.
MCAG cash in trust of $69M; assumes 75% redemptions; $17.25M retained.
AUM is a precision oncology company with pipeline in Phase 2 for AUM001 and AUM601.
Expected close Q1 2023, subject to customary conditions and approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.